Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0 | 0 | 5 | 5 | 11 | 0 | -2 | 4 |
| Operating profit | €m | -251 | -241 | ||||||
| Net profit | €m | -38 | -42 | -61 | -148 | -176 | -336 | -353 | -257 |
| EPS reported | € | -4.83 | -4.71 | ||||||
| Operating cashflow per share | € | -2.33 | -1.85 | ||||||
| Capex per share | € | 0.00 | 0.00 | ||||||
| FCF per share | € | -2.33 | -1.85 | ||||||
| Free cash flow | €m | -162 | -148 | ||||||
| Net debt | €m | -500 | -411 | ||||||
| Book value equity | €m | 455 | 366 | ||||||
| Book value per share | € | 6.55 | 4.60 | ||||||
| Number of shares | m | 69.53 | 79.65 | ||||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 18.39 | 19.87 | ||||||
| P/S LTM | x | 0.00 | -3,608.29 | ||||||
| P/FCF LTM | x | -51.60 | -49.29 | ||||||
| EV/EBITDA LTM | x | -31.60 | -24.67 | ||||||
| EV/Sales LTM | x | 0.00 | -3,404.68 | ||||||
| Earnings Yield LTM | % | -4.02% | -5.30% | ||||||
| FCF Yield | % | -1.94% | -2.03% | ||||||
| Quality | |||||||||
| ROE | % | -73.84% | -85.88% | ||||||
| ROIC | % | -47.96% | -60.98% | ||||||
| Operating margin | % | 0.00% | 11950.4% | ||||||
| Gross margin | % | 0.00% | 153.15% | ||||||
| FCF/Sales | % | - | 7320.4% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -100.00% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -5.06 | -121.83 | ||||||
| Net Debt/EBITDA | x | 1.94 | 1.39 | ||||||
| EBIT/Net interest | x | -8.79 | -9.37 | ||||||
| Net debt/market cap | % | -5.97% | -5.64% | ||||||
| Net debt/Equity | x | -1.10 | -1.12 | ||||||
| Gross debt/equity | x | 0.07 | 0.00 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free